Search - tctmd.com

Displaying 1 - 20 of 63

Sort: Relevancy | Date

News Daily News

CVD Still the Leading Cause of Death and Disease Globally

Michael O'Riordan

September 24, 2025

News Conference News ESC 2025

ESC Guidelines Update Clarifies Pregnancy Risks and Choices in Women With CVD

L.A. McKeown

September 09, 2025

News Daily News

Heart Disease Deaths Decline Over Last 50 Years, but Not Across the Board

Michael O'Riordan

June 25, 2025

News Daily News

Cardiotoxicity Rare With Common GI Chemotherapy

L.A. McKeown

April 15, 2025

News Conference News THT 2025

Tirzepatide Helps in HFpEF Across Spectrum of Obesity Severity

Todd Neale

February 12, 2025

News Opinion CV Team Dispatch

January 2025 Dispatch for the CV Team

L.A. McKeown

January 24, 2025

SUMMIT: Tirzepatide ‘Huge Win’ for HFpEF Patients With Obesity

News Conference News AHA 2024

SUMMIT: Tirzepatide a ‘Huge Win’ for HFpEF Patients With Obesity

Michael O'Riordan

November 16, 2024

News Conference News HFSA 2024

Semaglutide Helps in HFpEF Irrespective of Frailty, Exercise Capacity

Todd Neale

October 01, 2024

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for August 2024

Caitlin E. Cox

September 03, 2024

News Conference News ESC 2024

FINEARTS-HF: Benefit of Finerenone Extends to HFmrEF and HFpEF Patients

Michael O'Riordan

September 01, 2024

News Opinion CV Team Dispatch

September 2024 Dispatch for the CV Team

L.A. McKeown

September 01, 2024

News Daily News

SUMMIT Meets Primary Endpoint for Safety, Efficacy of Tirzepatide: Topline Results

Yael L. Maxwell

August 01, 2024

News Daily News

Reduced Vascular Load, Better RV Function With Dapagliflozin in HFpEF

Michael O'Riordan

July 26, 2024

News Daily News

Aligning Pill Burden and Palliative Care Needs in Late-Stage CVD: AHA

L.A. McKeown

July 02, 2024

News Opinion CV Team Dispatch

July 2024 Dispatch for the CV Team

L.A. McKeown

July 01, 2024

News Daily News

Semaglutide Has Similar Benefits in Women and Men With HFpEF

Todd Neale

June 26, 2024

News Daily News

Vutrisiran, an siRNA for ATTR-CM, Meets Primary Endpoint in HELIOS-B

Michael O'Riordan

June 24, 2024

News Conference News ESC Heart Failure 2024

Better Natriuresis With IV Furosemide and Metolazone in Chronic HF Patients

Michael O'Riordan

May 13, 2024

News Conference News ESC Heart Failure 2024

SEQUOIA-HCM: Aficamten Boosts Exercise Capacity in Obstructive HCM

Michael O'Riordan

May 13, 2024

News Daily News

SGLT2 Inhibitor Added to GDMT in Functional MR May Obviate Need for TEER

Michael O'Riordan

May 07, 2024

Advertisement

CVD Still the Leading Cause of Death and Disease Globally

ESC Guidelines Update Clarifies Pregnancy Risks and Choices in Women With CVD

Heart Disease Deaths Decline Over Last 50 Years, but Not Across the Board

Cardiotoxicity Rare With Common GI Chemotherapy

Tirzepatide Helps in HFpEF Across Spectrum of Obesity Severity

January 2025 Dispatch for the CV Team

SUMMIT: Tirzepatide a ‘Huge Win’ for HFpEF Patients With Obesity

Semaglutide Helps in HFpEF Irrespective of Frailty, Exercise Capacity

TCTMD’s Top 10 Most Popular Stories for August 2024

FINEARTS-HF: Benefit of Finerenone Extends to HFmrEF and HFpEF Patients

September 2024 Dispatch for the CV Team

SUMMIT Meets Primary Endpoint for Safety, Efficacy of Tirzepatide: Topline Results

Reduced Vascular Load, Better RV Function With Dapagliflozin in HFpEF

Aligning Pill Burden and Palliative Care Needs in Late-Stage CVD: AHA

July 2024 Dispatch for the CV Team

Semaglutide Has Similar Benefits in Women and Men With HFpEF

Vutrisiran, an siRNA for ATTR-CM, Meets Primary Endpoint in HELIOS-B

Better Natriuresis With IV Furosemide and Metolazone in Chronic HF Patients

SEQUOIA-HCM: Aficamten Boosts Exercise Capacity in Obstructive HCM

SGLT2 Inhibitor Added to GDMT in Functional MR May Obviate Need for TEER

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content